Krystal Biotech, Inc.
NASDAQ:KRYSBiotechnology
+$18.29 today
- Market cap
- $9.34B
- Beta
- 0.53
- P/E (TTM)
- 44.5
- EPS (TTM)
- $7.68
Volume 0.35M
Average 0.29M
KRYS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Krystal Biotech, Inc.NASDAQ: KRYS
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $39.85M rose 13.3% year over year, behind the +24.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 2.8% from the prior quarter. Over 3 fiscal years it compounded at +23.6% a year.
Context
- Selling, general & admin amounted to 37.7% of revenue in FY2025, down 1.4 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $468.59M (+219.3%) for the fiscal year ending Dec 2026, a step up from the +29.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $39.85M-2.8% QoQ
- Last fiscal yearDec 2025
- $146.74M+29.1% YoY
- LTMJun 2026
- $159.72M+24.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 146.74M USD
- Year-over-year change
- +29.1%
- 4-year CAGR
- +38.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 146.74M | +29.1% |
| FY2024 | 2024-12-31 | 113.69M | +15.5% |
| FY2023 | 2023-12-31 | 98.4M | +26.6% |
| FY2022 | 2022-12-31 | 77.74M | +92.5% |
| FY2021 | 2021-12-31 | 40.39M | — |
Selling, General & Admin vs competitors
How KRYS compares with its peers on the latest reported figures
- KRYS's LTM Jun 2026 selling, general & admin of $159.72M is the highest of the 6 companies compared; the peer median is $73.88M.
- Its year-over-year change of +24.9% is the 2nd highest of 6, against a peer median of -2.3%.
- Selling, general & admin amounts to 36.3% of revenue for KRYS, versus a peer median of 95.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $159.72M | +24.9% | +23.6% | 36.3% | |
| LTM Mar 2026 | $83.82M | +6.5% | -1.0% | 95.4% | |
| LTM Mar 2026 | $75.11M | -30.1% | +13.7% | — | |
| LTM Mar 2026 | $73.88M | +132.8% | +55.6% | 508.1% | |
| LTM Mar 2026 | $52.46M | -2.3% | +4.4% | 65.8% | |
| LTM Mar 2026 | $44.27M | -25.3% | -14.8% | — | |
| Peer median (excluding KRYS) | $73.88M | -2.3% | +4.4% | 95.4% | |
Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 50.7M | 290.52M | 389.13M |
| Cost of Revenue | 0 | 0 | 3.09M | 20.06M | 28.77M |
| Gross Profit | 0 | 0 | 47.61M | 270.45M | 360.36M |
| Gross Margin | — | — | 93.9% | 93.1% | 92.6% |
| Research & Development | 27.88M | 42.46M | 46.43M | 53.57M | 58.05M |
| Selling, General & Admin | 40.39M | 77.74M | 98.4M | 113.69M | 146.74M |
| Operating Expenses | 68.28M | 145.2M | 157.33M | 204.76M | 199.06M |
| Depreciation & Amortization | 2.77M | 4.05M | 5.01M | 6.71M | 6.55M |
| EBITDA | (65.31M) | (116.14M) | (92.22M) | 109.91M | 196.02M |
| EBITDA Margin | — | — | -181.9% | 37.8% | 50.4% |
| Operating Income | (68.28M) | (145.2M) | (109.73M) | 65.7M | 161.3M |
| Operating Margin | — | — | -216.4% | 22.6% | 41.5% |
| Interest Income | 197K | 5.22M | 22.62M | 29.66M | 28.18M |
| Interest Expense | 1.49M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.3M) | 5.22M | 122.62M | 29.66M | 28.18M |
| Income Before Tax | (69.57M) | (139.98M) | 12.9M | 95.36M | 189.47M |
| Pre-Tax Margin | — | — | 25.4% | 32.8% | 48.7% |
| Income Tax Expense | 0 | 0 | 1.97M | 6.2M | (15.36M) |
| Net Income | (69.57M) | (139.98M) | 10.93M | 89.16M | 204.83M |
| Net Margin | — | — | 21.6% | 30.7% | 52.6% |
| EPS (Basic) | (3.13) | (5.49) | 0.40 | 3.12 | 7.08 |
| EPS (Diluted) | (3.13) | (5.49) | 0.39 | 3.00 | 6.84 |
| Weighted Avg Shares | 22.2M | 25.49M | 27.15M | 28.59M | 28.94M |
| Weighted Avg Shares (Diluted) | 22.2M | 25.49M | 27.75M | 29.74M | 29.95M |
Krystal Biotech, Inc.
NASDAQ:KRYS
Intrinsic Alpha fair value
Locked
Current Price
$315.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.